Record Details

Radiolabelled trastuzumab Fab as a theranostic molecule for HER2 positive breast cancers

DIR@IMTECH: CSIR-Institute of Microbial Technology

View Archive Info
 
 
Field Value
 
Title Radiolabelled trastuzumab Fab as a theranostic molecule for HER2 positive breast cancers
 
Creator Rathore, Y.
Shukla, J.
Mittal, B. R.
Singh, G.
Gopal, K.
Kumar, R.
Bal, A.
Laroiya, I.
Lakhanpal, T.
 
Subject QR Microbiology
 
Description Inherited genes, hormonal imbalance, environmental factors, and mutation in genes are responsible for the development of breast cancer in females. Nowadays, passive immunotherapy is used to combat cancer. Trastuzumab is a humanized monoclonal antibody (mAb) and has a pronounced effect when used as adjuvant therapy, but high doses (4-8 mg/kg) and greater molecular weight (MW) increases liver retention. To fill this hiatus, antibody fragments (Fab) are generated and showed similar target specificity. The radiolabelling of Fab may provide the theranostic application in breast cancer patients.
 
Publisher ESMO
 
Date 2021-05-01
 
Type Article
PeerReviewed
 
Relation https://www.annalsofoncology.org/article/S0923-7534(21)00972-8/fulltext
http://crdd.osdd.net/open/2765/
 
Identifier Rathore, Y. and Shukla, J. and Mittal, B. R. and Singh, G. and Gopal, K. and Kumar, R. and Bal, A. and Laroiya, I. and Lakhanpal, T. (2021) Radiolabelled trastuzumab Fab as a theranostic molecule for HER2 positive breast cancers. ANNALS OF ONCOLOGY, 32 (2). S55-S56.